Japan's Eisai says US introduction of Alzheimer's drug Leqembi slower than expected

Japanese drugmaker Eisai on Thursday said the distribution of its Alzheimer's drug Leqembi in the United States has proceeded slower than it expected.
The company expects to reach 90% of its target for integrated delivery networks (IDNs) used to administer the drug in the U.S. in the fiscal year ending this month, Chief Executive Haruo Naito said.